In addition, inhibition of the MAPK pathway using EGFR and MEK inhibitors prevented expression of PD-L1 at the transcriptional and translational levels in non-small cell lung cancer (NSCLC) [221]. Here, EGFR is linked to non-small cell lung carcinoma.